Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
87 hedge funds and large institutions have $213M invested in Progenics Pharmaceuticals Inc in 2014 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 22 reducing their positions, and 7 closing their positions.
243% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 7
36% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 22
24% more funds holding
Funds holding: 70 → 87 (+17)
4% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $1.24M
15% less capital invested
Capital invested by funds: $251M → $213M (-$37.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$8.11M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$5.11M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.79M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.65M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$2.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.03M |
| 2 |
D.E. Shaw & Co
New York
|
-$2.02M |
| 3 |
JG
Jefferies Group
New York
|
-$831K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$570K |
| 5 |
MCM
Moore Capital Management
New York
|
-$506K |
PGNX Hedge Fund Activity: Q1 2014 in Review
87 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2014, worth a combined $213M — down 15% from $251M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PGNX positions and 7 closed out — a net gain of 17 holders — while 30 added to existing stakes and 22 trimmed.
The largest buyer was Broadfin Capital, adding an estimated $8.11M. The largest seller was Fidelity Investments, cutting an estimated $9.03M.
- 87 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2014, up from 70 in Q4 2013.
- Funds reported $213M of Progenics Pharmaceuticals Inc stock for Q1 2014, down 15% quarter-over-quarter.
- 24 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2014 and 7 closed out, a net change of +17 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q1 2014 was Broadfin Capital, an estimated $8.11M added.
- The largest Progenics Pharmaceuticals Inc seller in Q1 2014 was Fidelity Investments, an estimated $9.03M sold.
Based on aggregated 13F filings for Q1 2014.